Drug
Tildrakizumab clinical trials
Also written MK-3222 and Ilumya.
- studies test it
- 19
- open now
- 2
- in phase 3
- 7
- first study started
- 2010
Keep track of what changes. Save the tildrakizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
19 studies that test it; most in 2020 (9)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2019 | 1 |
| 2020 | 9 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 9
Sun Pharmaceutical Industries Limited (6) · University of California, San Francisco (2) · Almirall, S.A. (2) · Radboud University Medical Center (1) · Marcelo F. Di Carli, MD, FACC (1) · Medical College of Wisconsin (1) · Premier Specialists, Australia (1) · Carlos Wambier (1)
Often tested with
Tested in the same studies.
Secukinumab (2) · Ixekizumab (2) · Guselkumab (2) · Risankizumab (2) · Bimekizumab (2) · Brodalumab (1) · Triamcinolone (1) · Fluorouracil (1)
Studies
Open first, then newest update. How each study uses tildrakizumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Tildrakizumab
- ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.RecruitingPhase 4Psoriasis Treatment Center of Central New JerseyNCT04347473Written as Ilumya Injectable Product
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.Active, not recruitingPhase 3Sun Pharmaceutical Industries LimitedNCT06611163Written as Tildrakizumab 100 mg
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque PsoriasisActive, not recruitingPhase 2/3Sun Pharmaceutical Industries LimitedNCT03997786Written as Tildrakizumab
- Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail PsoriasisCompletedPhase 3Sun Pharmaceutical Industries LimitedNCT03897075Written as Tildrakizumab
- Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedPhase 4Radboud University Medical CenterNCT04340076Written as Tildrakizumab
- MIcrovascular dysfuNction In Moderate-severe PsoriasisCompletedPhase 4Marcelo F. Di Carli, MD, FACCNCT04271540Written as Tildrakizumab
- Tildrakizumab for Prevention of Acute Graft-Versus-Host DiseaseCompletedPhase 2Medical College of WisconsinNCT04112810Written as Tildrakizumab
- Pilot Study Assessing the Effect of Tildrakizumab in VitiligoCompletedEarly Phase 1Premier Specialists, AustraliaNCT04971200Written as Tildrakizumab
- Effects of Tildrakizumab on Epigenetic AgeCompletedPhase 4Carlos WambierNCT05110313Written as TILDRAKIZUMAB
- Predicting Inflammatory Skin Disease Response to IL-23 BlockadeCompletedPhase 4University of California, San FranciscoNCT04541329Written as Tildrakizumab
- Abiraterone Acetate in Combination With TildrakizumabTerminatedPhase 1/2Institute of Cancer Research, United KingdomNCT04458311Written as Tildrakizumab
- A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype PsoriasisCompletedPhase 3Shenzhen Kangzhe Pharmaceutical Co., Ltd.NCT05108766Written as Tildrakizumab 100 mg
- Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)CompletedPhase 4Almirall, S.A.NCT04229836Written as Tildrakizumab 100 mg Solution for Injection
- A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)CompletedPhase 3Sun Pharmaceutical Industries LimitedNCT01722331Written as Tildrakizumab 200 mg
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)CompletedPhase 3Sun Pharmaceutical Industries LimitedNCT01729754Written as Tildrakizumab 200 mg
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)WithdrawnPhase 3Sun Pharmaceutical Industries LimitedNCT01936688Written as MK-3222 200 mg
- Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque PsoriasisTerminatedPhase 4Almirall, S.A.NCT04339595Written as Tildrakizumab
- A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01225731Written as tildrakizumab
Given in every arm · 1 — tildrakizumab is usual care beside what is tested
Codes
What other systems call tildrakizumab · ClinicalTrials.gg INT000235
- MeSH (NLM) C000598434tildrakizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DEW6X41BEKTILDRAKIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2053436Confirmed FDA, Wikidata
- Wikidata Q15708331tildrakizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152627TildrakizumabOne source FDA
- DrugBank DB14004One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598434 | tildrakizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DEW6X41BEK | TILDRAKIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2053436 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708331 | tildrakizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152627 | Tildrakizumab | One source FDA |
| DrugBank | DB14004 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.